How many companies will be left standing once consolidation hits the AI in healthcare sector? Which pharma companies are ...

Pfizer claims Metsera breached their merger agreement, adding that a tie-up of the biotech with GLP-1 drug giant Novo Nordisk ...

With federal PBM reform stalled, states like California are stepping up with laws like SB 41 to boost transparency and lower ...

Every day, Americans benefit from consumer-friendly technology that has radically improved every aspect of their lives. But these benefits have lagged in healthcare due to its distinct complexities ...

Hospital M&A activity is expected to increase this year — and the sector has already begun 2024 with a bang. The merger was one of the biggest hospital M&A deals announced last year. The combined ...

Over the past several years, pharmaceutical companies have been steadily integrating artificial intelligence (AI) into many aspects of clinical development. Today, AI’s impact is being felt from the ...

Two obesity drugs are among the six new medications that could get faster FDA review under a new pilot program open to products addressing certain national health priorities. Rare and infectious ...

In a Monday letter, a group of 350 organizations urged Congress to make Covid-19 Medicare telehealth flexibilities permanent. If Congress can’t make these flexibilities —which are set to expire in ...

In the rare disease hereditary angioedema, or HAE, painful swelling attacks can happen anywhere in the body without warning. Drugs are available for acute treatment of these attacks, but they’re all ...

Function Health, a membership-based platform that gives consumers access to more than 100 different lab tests, on Tuesday announced the close of a sizable funding round — one that includes about a ...

About one in six working adults in the U.S. battle a substance use disorder, and nearly 10% of U.S. employees have a cannabis or stimulant use disorder. Recognizing this, Carrum Health has expanded ...

In a drug discovery career spanning more than two decades, Alex Lugovskoy has seen a lot of antibodies come and go. The vast majority of them work by inhibiting a cellular function. Lugovskoy, now the ...